STAAR Surgical Company Share Price

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
46.96 USD +0.15% Intraday chart for STAAR Surgical Company +1.23% +50.46%
Sales 2024 * 339M 27.11B Sales 2025 * 394M 31.57B Capitalization 2.26B 181B
Net income 2024 * - 0 Net income 2025 * 26M 2.08B EV / Sales 2024 * 5.81 x
Net cash position 2024 * 292M 23.41B Net cash position 2025 * 313M 25.07B EV / Sales 2025 * 4.93 x
P/E ratio 2024 *
2,609 x
P/E ratio 2025 *
104 x
Employees 1,057
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.15%
1 week+1.23%
Current month+22.68%
1 month+30.44%
3 months+58.81%
6 months+22.80%
Current year+50.46%
More quotes
1 week
45.42
Extreme 45.42
49.13
1 month
37.35
Extreme 37.352
52.68
Current year
26.66
Extreme 26.6554
52.68
1 year
26.66
Extreme 26.6554
73.13
3 years
26.66
Extreme 26.6554
163.08
5 years
21.70
Extreme 21.7001
163.08
10 years
4.84
Extreme 4.84
163.08
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 31/05/20
Director of Finance/CFO 51 05/07/20
Chief Operating Officer 48 23/04/23
Members of the board TitleAgeSince
Director/Board Member 59 31/12/15
Director/Board Member 55 15/06/22
Chief Executive Officer 68 31/05/20
More insiders
Date Price Change Volume
26/04/24 46.96 +0.15% 335,626
25/04/24 46.89 -1.94% 350,028
24/04/24 47.82 -0.77% 571,217
23/04/24 48.19 +3.52% 749,032
22/04/24 46.55 +0.34% 246,628

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
46.96 USD
Average target price
49.17 USD
Spread / Average Target
+4.70%
Consensus